Home/Xilio Therapeutics/Mary Ann Gray
MA

Mary Ann Gray

Chief Financial Officer

Xilio Therapeutics

Therapeutic Areas

Xilio Therapeutics Pipeline

DrugIndicationPhase
XTX101Advanced solid tumorsPhase 1
XTX202Advanced solid tumorsPhase 1
XTX301Advanced solid tumorsPreclinical
XTX401Advanced solid tumorsPreclinical